Released Mar 10, 2021, before the open
10-K filed Mar 12, 2021, 71 days after period end · 0001171843-21-001737
Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$30.98M$30.98M derived+0.0% vs Q4 2019+28.9% vs Q3 2020
Net Income-$615.00K-$615.00K derivedN/M vs Q4 2019N/M vs Q3 2020
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$17,708,000+2.8%
Operating Incomederived$2,756,000+68.8%
Operating Cash Flowderived$2,490,000+12.2%
Free Cash Flowderived$2,426,000+36.1%
Margins · derived
Gross margin57.2%+1.5 pt vs Q4 2019
Operating margin8.9%+3.6 pt vs Q4 2019
Net margin-2.0%−3.8 pt vs Q4 2019
What the release said
The release
Same quarter
| Metric | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $30.98M | $30.97M | $33.86M | $21.65M |
| Net Income | -$615.00K | $550.00K | $2.86M | $999.00K |
| EPS Diluted | — | $0.02 | $0.08 | $0.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR